Diversified Trust Co Purchases 577 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

Diversified Trust Co grew its position in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 5.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,293 shares of the medical instruments supplier’s stock after purchasing an additional 577 shares during the quarter. Diversified Trust Co’s holdings in Merit Medical Systems were worth $855,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Valued Wealth Advisors LLC bought a new position in shares of Merit Medical Systems in the fourth quarter valued at approximately $29,000. Parallel Advisors LLC raised its position in shares of Merit Medical Systems by 114.6% in the fourth quarter. Parallel Advisors LLC now owns 397 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 212 shares during the period. Tompkins Financial Corp bought a new position in shares of Merit Medical Systems in the fourth quarter valued at approximately $38,000. Kapitalo Investimentos Ltda acquired a new stake in shares of Merit Medical Systems in the fourth quarter worth $96,000. Finally, Quadrant Capital Group LLC grew its stake in shares of Merit Medical Systems by 60.7% in the fourth quarter. Quadrant Capital Group LLC now owns 2,126 shares of the medical instruments supplier’s stock worth $161,000 after acquiring an additional 803 shares during the last quarter. Institutional investors own 99.66% of the company’s stock.

Wall Street Analyst Weigh In

MMSI has been the topic of several research analyst reports. Canaccord Genuity Group raised their price objective on shares of Merit Medical Systems from $102.00 to $125.00 and gave the stock a “buy” rating in a research note on Tuesday. Barrington Research restated an “outperform” rating and issued a $100.00 price objective on shares of Merit Medical Systems in a research note on Tuesday. Baird R W upgraded shares of Merit Medical Systems to a “strong-buy” rating in a research note on Friday, June 28th. Robert W. Baird assumed coverage on shares of Merit Medical Systems in a research note on Friday, June 28th. They issued an “outperform” rating and a $96.00 price objective on the stock. Finally, StockNews.com upgraded shares of Merit Medical Systems from a “hold” rating to a “buy” rating in a research note on Thursday, June 27th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Merit Medical Systems has a consensus rating of “Buy” and a consensus price target of $96.20.

Insider Activity

In related news, COO Neil Peterson sold 7,500 shares of Merit Medical Systems stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $81.85, for a total value of $613,875.00. Following the completion of the transaction, the chief operating officer now directly owns 14,819 shares of the company’s stock, valued at $1,212,935.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director F. Ann Millner sold 12,500 shares of Merit Medical Systems stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $85.00, for a total value of $1,062,500.00. Following the completion of the transaction, the director now directly owns 32,391 shares of the company’s stock, valued at $2,753,235. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Neil Peterson sold 7,500 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $81.85, for a total value of $613,875.00. Following the sale, the chief operating officer now directly owns 14,819 shares of the company’s stock, valued at $1,212,935.15. The disclosure for this sale can be found here. 3.70% of the stock is owned by corporate insiders.

Merit Medical Systems Stock Up 1.0 %

Shares of NASDAQ:MMSI opened at $86.50 on Wednesday. Merit Medical Systems, Inc. has a 52 week low of $62.58 and a 52 week high of $87.44. The company has a debt-to-equity ratio of 0.65, a quick ratio of 4.38 and a current ratio of 6.03. The company’s fifty day moving average is $81.10 and its 200-day moving average is $77.85. The company has a market capitalization of $5.03 billion, a PE ratio of 49.71, a P/E/G ratio of 2.40 and a beta of 0.88.

Merit Medical Systems (NASDAQ:MMSI) last issued its earnings results on Tuesday, April 30th. The medical instruments supplier reported $0.77 EPS for the quarter, beating the consensus estimate of $0.71 by $0.06. Merit Medical Systems had a net margin of 7.94% and a return on equity of 15.02%. The company had revenue of $323.51 million for the quarter, compared to the consensus estimate of $315.57 million. During the same quarter in the previous year, the company earned $0.64 EPS. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. Equities research analysts predict that Merit Medical Systems, Inc. will post 3.33 earnings per share for the current fiscal year.

Merit Medical Systems Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.